We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEssentra Regulatory News (ESNT)

Share Price Information for Essentra (ESNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 174.40
Bid: 173.60
Ask: 174.20
Change: -2.80 (-1.58%)
Spread: 0.60 (0.346%)
Open: 176.00
High: 177.20
Low: 173.00
Prev. Close: 177.20
ESNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition of 3C! Packaging, Inc.

17 Sep 2020 16:36

RNS Number : 3522Z
Essentra plc
17 September 2020
 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014

 

17 September 2020

 

Essentra PLC

 

Acquisition of 3C! Packaging, Inc.

 

Introduction

Essentra PLC ("Essentra" or the "Company"), a leading global provider of essential components and solutions, today announces that it has signed a sale and purchase agreement (the "SPA") to purchase the entire issued share capital of 3C! Packaging, Inc. ("3C!") from each of Joseph Elphick, the Joseph Gerard Elphick Revocable Trust U/A/D November 5, 2010 and the Joseph G Elphick Legal Trust U/A/D December 21, 2021 (the "Acquisition") on a cash free, debt free basis, for total consideration of $65 million (approximately £50 million1) (the "Consideration"), with completion today. The Consideration has been paid in cash.

3C!, headquartered in North Carolina, USA, is a leading designer and manufacturer of custom folding cartons, printed literature, foil and flexible packaging and labels focused on the pharmaceuticals and healthcare sectors. On completion of the Acquisition, 3C! will join Essentra's Packaging division.

The Acquisition meets Essentra's strategic and financial criteria, by creating significant value, strengthening the Company's customer proposition and offering significant synergies.

Highlights of the Acquisition include:

- 3C! is a strategically located and industry leading packaging business, allowing Essentra to enhance its position in the pharmaceutical packaging space;

- the Acquisition is expected to further strengthen Essentra's industry leading packaging business, adding long-standing relationships with key blue-chip customers in the US pharmaceutical sector;

- creation of a North Carolina hub with three sites positioned in the number one pharmaceutical manufacturing area of the USA;

- 3C!'s leading, proprietary serialisation technology will supplement the Company's added value services;

- the 3C! leadership team will join the Company, providing significant experience in speciality packaging and serving the US pharmaceutical market;

- the Consideration represents a 5.7x multiple of pro-forma 3C! adjusted EBITDA of $7.3m (year to 30 June 2020) plus anticipated c.$4m synergies2,3,4;

- Acquisition meets internal ROIC benchmark by year 3; and

- revenue and margin synergies are expected from combining the Company's and 3C!'s customer base, optimised carton competitiveness and procurement synergies.

Paul Forman, Chief Executive Officer of Essentra, commented:

"3C! is a strong fit for Essentra with excellent growth prospects. The business further strengthens our position in pharmaceutical and healthcare packaging in core product areas we know well, in addition to bringing valuable new innovation to Essentra with its serialisation technology. The acquisition of 3C! follows the successful integration of Nekicesa which has performed strongly in the first year of Essentra ownership. With 3C! we will continue to build the Packaging division's track record for identifying, acquiring and integrating high quality businesses that meet our disciplined criteria and deliver sustainable value to Essentra over the long-term."

3C! overview

3C! is a leading designer and manufacturer of custom folding cartons, printed literature, foil and flexible packaging and labels, with 91%2 of revenue in the year to 30 June 2020 generated from pharmaceutical and healthcare customers.

Founded in 1979, 3C! is a privately held, family owned business headquartered in North Carolina, USA. The business is strategically located close to some of the biggest pharmaceutical clients in the US and has long-standing relationships with key blue-chip customers.

3C! is led by a highly experienced management team with significant experience in speciality packaging and serving the pharmaceutical market. It has a workforce of 280 multiskilled, cross-trained employees.

3C! has a strong financial track record of revenue and margin growth. Between 2016 and 2020, 3C!'s revenue grew at a compound annual growth rate ("CAGR") of 11.5%2. In the year to 30 June 2020, 3C! delivered revenue of $48.8 million2 at an adjusted EBITDA margin of 14.9%2,4. In the year to 30 June 2020, revenue was split approximately: 60%2 (folding cartons), 29%2 (printed literature) and 11%2 (flexible packaging and labels). 3C! has a state-of-the-art design centre and offers additional value add services, including its proprietary serialisation technology.

3C! is well-positioned for further development, given the compelling end-market dynamics of the packaging industry and 3C!'s organic growth initiatives. The Company anticipates additional revenue opportunities for 3C! through additional cross selling product opportunities with its existing strong, blue-chip customer base, new blue-chip customers onboarding and new product offerings and initiatives. There is also significant margin improvement and opportunities through lean manufacturing initiatives, increasing efficiency and reducing costs. The Company expects c.$4m in annual recurring synergies by year 3 delivered primarily through cost synergies, largely through network optimisation and procurement, continuous improvement and applying Essentra supplier arrangements and expertise. The cost to achieve these synergies of $3.2m is spread over the next 2 years. Further, the acquisition significantly accelerates the ability to recognize $4.3m (after tax) of deferred tax assets.

As at 30 June 2020, 3C! had gross assets of $18.9 million2 and Profit before Tax of $3.0 million2 in the year to 30 June 2020.

The Acquisition constitutes a Class 2 transaction for the purposes of the FCA's Listing Rules.

The person responsible for releasing this announcement is Jon Green (General Counsel & Company Secretary).

1 Based on GBP:USD exchange rate of 1.30 as of 16 September 2020

2 Based on reviewed, unaudited financial information

3 Full year synergies expected to be achieved by year 3

4 Adjustments made to 3C! Packaging management's adjusted EBITDA of c.$7.9m total c.$0.6m of downward adjustments and comprise adjustments for COVID-19 related payroll tax credits, reversing an inventory reserve, normalising travel expenses post COVID-19, a customer rebate and normalised bonus adjustments.

 

For further information please contact:

Essentra PLC

Paul Forman, Chief Executive

Lily Liu, Chief Financial Officer

Aamir Mohiuddin, Investor Relations Director

Lucy Yank, Group Communications Director

 

via Tulchan

Tulchan Communications LLP (Financial PR)

Martin Robinson / Sophia Martin-Pavlou / Olivia Peters

+44 (0)20 7353 4200

 

IMPORTANT NOTICES

This Announcement is not for public release, publication, distribution or forwarding, in whole or in part, directly or indirectly, in or into the United States, Australia, Canada, the Republic of South Africa, Japan or any other jurisdiction in which such release, publication, distribution or forwarding would be unlawful.

All information regarding 3C! is based on information provided by the management of 3C! and has not been independently verified and accordingly, each of the Company, Jefferies, Peel Hunt, their respective affiliates and their respective Representatives expressly disclaim, to the maximum extent permitted by law, any responsibility or liability arising in connection with the information in this Announcement relating to 3C! Unless otherwise indicated, historical financial information relating to 3C! has been extracted without adjustment from 3C!'s financial statements. Such financial statements have not been audited but reviewed, the objective of which is not to express an opinion regarding the financial statements as a whole. A review is substantially less in scope than an audit and in this case was limited to the application of analytical procedures to management's financial data and making inquiries of 3C!'s management. The information in this Announcement is subject to change.

Certain statements in this Announcement are forward-looking statements with respect to the Company's expectations, intentions and projections regarding its future performance, strategic initiatives, anticipated events or trends and other matters that are not historical facts and which are, by their nature, inherently predictive, speculative and involve risks and uncertainty because they relate to events and depend on circumstances that may or may not occur in the future. All statements that address expectations or projections about the future, including statements about operating performance, strategic initiatives, objectives, market position, industry trends, general economic conditions, expected expenditures, expected cost savings and financial results are forwardlooking statements. Any statements contained in this Announcement that are not statements of historical fact are, or may be deemed to be, forwardlooking statements. These forward-looking statements, which may use words such as "aim", "anticipate", "believe", "could", "intend", "estimate", "expect", "may", "plan", "project" or words or terms of similar meaning or the negative thereof, are not guarantees of future performance and are subject to known and unknown risks and uncertainties. There are a number of factors including, but not limited to, commercial, operational, economic and financial factors, that could cause actual results, financial condition, performance or achievements to differ materially from those expressed or implied by these forwardlooking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as changes in taxation or fiscal policy, future market conditions, currency fluctuations, the behaviour of other market participants, the actions of governments or governmental regulators, or other risk factors, such as changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including inflation, recession and consumer confidence, on a global, regional or national basis. Given those risks and uncertainties, readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of this Announcement. Each of the Company, Jefferies and Peel Hunt expressly disclaims any obligation or undertaking to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise unless required to do so by applicable law or regulation.

No statement in this Announcement is intended to be a profit forecast or profit estimate for any period and no statement in this Announcement should be interpreted to mean that earnings, earnings per share or income, cash flow from operations or free cash flow for the Company for the current or future financial periods would necessarily match or exceed the historical published earnings, earnings per share or income, cash flow from operations or free cash flow for the Company.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQBUGDCBXBDGGR
Date   Source Headline
19th Apr 20242:28 pmRNSDirector/PDMR Shareholding
19th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20247:00 amRNSTransaction in Own Shares
16th Apr 20247:00 amRNSTransaction in Own Shares
15th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares
10th Apr 20247:00 amRNSTransaction in Own Shares
9th Apr 20247:00 amRNSTransaction in Own Shares
8th Apr 20247:00 amRNSTransaction in Own Shares
5th Apr 20241:35 pmRNSDirector/PDMR Shareholding
5th Apr 20241:35 pmRNSDirector/PDMR Shareholding
5th Apr 20247:00 amRNSTransaction in Own Shares
4th Apr 20242:08 pmRNSDirector/PDMR Shareholding
4th Apr 202411:00 amRNSNotice of AGM
4th Apr 20247:00 amRNSTransaction in Own Shares
3rd Apr 202411:26 amRNSTransaction in Own Shares
2nd Apr 20242:51 pmRNSDirector/PDMR Shareholding
2nd Apr 20247:00 amRNSTotal Voting Rights
28th Mar 20244:18 pmRNSPublication of 2023 Annual Report
28th Mar 20247:00 amRNSTransaction in Own Shares
27th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 20247:00 amRNSTransaction in Own Shares
21st Mar 20247:00 amRNSTransaction in Own Shares
19th Mar 20247:00 amRNSDirectorate Change
19th Mar 20247:00 amRNSResults for the Full Year Ended 31 December 2023
19th Mar 20247:00 amRNSTransaction in Own Shares
18th Mar 20247:00 amRNSTransaction in Own Shares
14th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20247:00 amRNSTransaction in Own Shares
12th Mar 20247:00 amRNSTransaction in Own Shares
11th Mar 20247:00 amRNSTransaction in Own Shares
8th Mar 20247:00 amRNSTransaction in Own Shares
7th Mar 20247:00 amRNSTransaction in Own Shares
6th Mar 20247:00 amRNSTransaction in Own Shares
5th Mar 20247:00 amRNSTransaction in Own Shares
4th Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20247:53 amRNSTotal Voting Rights
29th Feb 20247:00 amRNSTransaction in Own Shares
28th Feb 20247:00 amRNSNotice of Full Year 2023 Results
28th Feb 20247:00 amRNSTransaction in Own Shares
27th Feb 20247:00 amRNSTransaction in Own Shares
26th Feb 20247:00 amRNSTransaction in Own Shares
23rd Feb 20247:00 amRNSTransaction in Own Shares
22nd Feb 20247:00 amRNSTransaction in Own Shares
21st Feb 20247:00 amRNSSBTi approval for near-term and net-zero targets
21st Feb 20247:00 amRNSTransaction in Own Shares
20th Feb 20247:00 amRNSTransaction in Own Shares
19th Feb 20247:00 amRNSTransaction in Own Shares
16th Feb 20247:00 amRNSTransaction in Own Shares
15th Feb 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.